【摘要】 目的观察痛泻要方加味治疗肠易激综合征(腹泻型)患者的临床疗效。方法将90例肠易激综合征(腹泻型)患者随机分为治疗组45例,对照组45例,其中治疗组口服痛泻要方加味并随症加减。对照组给予口服思密达,观察两组患者的临床常见症状改善情况。结果两组患者治疗前常见症状积分比较差异无统计学意义(P>0.05)。治疗4周后治疗组在腹痛、泄泻、郁怒或紧张、胸胁胀闷、嗳气、纳差、肠鸣矢气等常见症状改善方面,均优于对照组,差异有统计学意义(P<0.05);治疗组在治疗4周后总有效率明显优于对照组,两组比较,差异有统计学意义(P<0.05)。结论痛泻要方对腹泻型肠易激综合征有较好的疗效,能明显缓解临床症状,缩短治疗时间,且无不良反应,值得临床推广。更多还原

【Abstract】 Objective To observe the clinical efficacy on irritable bowel syndrome(IBS)(diarrhea type)treated with the modified tongxie yaofang.Method 90 cases of IBS(diarrhea type)were randomized into a treatment group(45 cases)and a control group(45 cases).In the treatment group,the modified tongxie yaofang was prescribed according to the symptoms for oral administration.In the control group,Smecta was prescribed for oral administration.The improvements in the clinical common symptoms were observed in two groups.Results The statistical significant difference was not indicated in the common symptom score before treatment in the comparison between two groups(P>0.05).In 4 weeks of treatment,the improvements in the common symptoms of the treatment group were superior to those of the control group,such as abdominal pain,diarrhea,anger or stress,distention in the chest and hypochondriac region,belching,poor appetite,borborygmus and flatus,presenting the statistical significant differences(P<0.05).In 4 weeks of treatment,the total effect of the treatment group was markedly superior to that of the control group,presenting the statistical significant difference(P<0.05).Conclusions Tongxie yaofang achieves the good efficacy on IBS(diarrhea type).It relieves remarkably the clinical symptoms,shortens the treatment time and has no adverse reactions.Hence,it deserves to be promoted clinically.更多还原